Vanguard Group Inc Eliem Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.37 Trillion
Q1 2025

A detailed history of Vanguard Group Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,502,556 shares of ELYM stock, worth $6.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,502,556

Previous 1,506,257 0.25%

Holding current value

$6.18 Million

Previous $6.19 Million 0.24%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	N/A	-3,701 Reduced 0.25%	1,502,556 $6.18 Million
Q4 2024 Feb 11, 2025	SELL	$4.11 - $5.42 $76,491 - $100,871	-18,611 Reduced 1.22%	1,506,257 $6.19 Million
Q3 2024 Nov 13, 2024	BUY	$4.98 - $8.93 $5.97 Million - $10.7 Million	1,198,487 Added 367.2%	1,524,868 $7.76 Million
Q2 2024 Aug 13, 2024	BUY	$2.6 - $10.2 $41,327 - $162,129	15,895 Added 5.12%	326,381 $2.32 Million
Q4 2023 Feb 14, 2024	BUY	$2.45 - $2.85 $1,629 - $1,895	665 Added 0.21%	310,486 $838,000
Q3 2023 Nov 14, 2023	BUY	$2.48 - $3.15 $87,553 - $111,207	35,304 Added 12.86%	309,821 $814,000
Q4 2022 Feb 10, 2023	BUY	$2.48 - $3.69 $310 - $461	125 Added 0.05%	274,517 $1.01 Million
Q2 2022 Aug 12, 2022	SELL	$2.77 - $8.4 $84,224 - $255,410	-30,406 Reduced 9.98%	274,392 $829,000
Q1 2022 May 13, 2022	SELL	$8.01 - $13.15 $12,471 - $20,474	-1,557 Reduced 0.51%	304,798 $2.56 Million
Q4 2021 Feb 14, 2022	BUY	$8.61 - $20.47 $919,212 - $2.19 Million	106,761 Added 53.49%	306,355 $3.2 Million
Q3 2021 Nov 12, 2021	BUY	$14.45 - $28.61 $2.88 Million - $5.71 Million	199,594 New	199,594 $3.59 Million

Others Institutions Holding ELYM

# of Institutions

Shares Held

49.8M

Call Options Held

Put Options Held

View Full List

About Eliem Therapeutics, Inc.

Ticker ELYM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,567,700
Market Cap $109M
Description
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...

More about ELYM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Eliem Therapeutics, Inc. Transaction History